Fresenius Kabi Pharmaceuticals Holding Inactive 10-Q2010 Q1 Quarterly report

Filed: 4 May 10, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: add, adjudicated, angina, Angiomax, announced, anticoagulant, assignee, ASU, back, bivalirudin, branded, breast, dispense, eligible, enacted, Fact, Gary, gemcitabine, Gemzar, Gopal, Health, healthcare, heard, HIT, Hrvatska, identification, Judge, Krishna, lung, MDL, Medicaid, mid, Musso, outpatient, ovarian, owner, pancreatic, pediatric, Pennsylvania, plead, prepaid, prescription, program, pushed, rebate, sensitivity, Southern, stop, Target, thrombocytopenia, underway, unstable, Virginia, West, withstand

Removed: accounted, acquiring, advanced, affecting, allocated, allocation, alternative, annum, applied, Article, audited, Bank, book, Branch, breach, breached, commercialization, comparative, component, consummation, converted, created, deductible, deferral, derived, detailed, determination, determine, Deutsche, developing, discount, discounted, discussing, dispositive, employee, enhanced, essentially, establishing, EURIBOR, Excluding, exercise, explicit, extended, facilitate, feasibility, firm, framework, fully, functional, GmbH, heparin, highlighted, historical, iii, impacted, implementation, implicit, improved, incorporated, increasing, invest, issuer, iv, leverage, London, maximizing, mix, model, monetary, Morgan, occurred, offsetting, opening, opinion, partial, partially, percentage, permit, plc, preceding, prepared, prevailing, project, ProServe, put, Ratio, registered, Regulation, relevant, relief, renew, renewal, repaid, repurchase, Rican, running, Section, separate, stage, statement, subsequent, succeeding, successor, Suisse, suit, swingline, technological, termination, thereto, Tranche, transition, treated, typically, undergoing, validation, vary, volume, yield

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Fresenius Kabi Pharmaceuticals Holding similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION

In connection with the periodic report of Fresenius Kabi Pharmaceuticals Holding, Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2010 as filed with the Securities and Exchange Commission (the “Report”), I, Richard J. Tajak, Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.


Date: May 3, 2010				/s/ Richard J. Tajak
				Richard J. Tajak
				Chief Financial Officer

This certification accompanies this Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.